TP53 and osteosarcoma: As shown in Figure 1A, CRISPR–Cas9-mediated knockout of PHLDA2 in human osteosarcoma U2OS cells had no obvious effect on p53 levels or p53 transcriptional ability, suggesting that PHLDA2 is not directly involved in modulating p53-dependent transcriptional activity.